COVID-19 impact in Q1 less than what Infosys envisaged: Infosys CEO

However uncertainty around recovery and “second wave” present challenges

Swathi Moorthy

June 28, 2020 / 14:45 IST

26 Aug, 2025 12:21

Volume

Todays L/H

India's second largest IT service major Infosys said that the impact of COVID-19 in June quarter was less than what it envisaged in April.

However uncertainty around recovery and “second wave” presents challenges, said Salil Parekh, CEO, Infosys.

This comes at the back of increasing investment in digital technologies by clients and opening up of many economies such as the US and countries in the EU.

Speaking at the 39th Annual General Meeting that was held virtually, Parekh said that in April, the company anticipated business impact in deal closures and longer decision cycles at the back of the pandemic.

“However the business impact is less than what we envisaged in April since many of the economies opened up with strong government fiscal monetary support. We have not seen large scale cancellations,” he added.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show